| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1004112136 |
| P356 | DOI | 10.1038/BJC.1997.194 |
| P932 | PMC publication ID | 2222780 |
| P698 | PubMed publication ID | 9099959 |
| P5875 | ResearchGate publication ID | 14117275 |
| P2093 | author name string | Sugimachi K | |
| Ishida T | |||
| Fukuyama Y | |||
| Mitsudomi T | |||
| Sugio K | |||
| Akazawa K | |||
| P2860 | cites work | Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene | Q24298218 |
| Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples | Q24569561 | ||
| A genetic model for colorectal tumorigenesis | Q27860582 | ||
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways | Q28253542 | ||
| Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms | Q28256462 | ||
| Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes | Q28265486 | ||
| ras oncogenes in human cancer: a review | Q29547769 | ||
| C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. | Q34124421 | ||
| N-myc can cooperate with ras to transform normal cells in culture | Q37528796 | ||
| Cooperation between oncogenes | Q37625799 | ||
| The p53 tumour suppressor gene | Q37751892 | ||
| Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis | Q38648510 | ||
| The molecular biology of lung cancer pathogenesis | Q40891672 | ||
| Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes | Q41946290 | ||
| The relationship of p53 immunostaining to survival in carcinoma of the lung | Q42125689 | ||
| p53 mutations in human lung tumors | Q43755264 | ||
| TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. | Q44964668 | ||
| Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines | Q46937946 | ||
| Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. | Q53520000 | ||
| Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. | Q53548575 | ||
| Participation of p53 cellular tumour antigen in transformation of normal embryonic cells | Q53548581 | ||
| Differential expression of c-myc gene and c-fos gene in premalignant and malignant tissues from patients with familial polyposis coli. | Q54743336 | ||
| Increased expression of mutant forms of p53 oncogene in primary lung cancer | Q58212568 | ||
| Mutations of the p53 Gene as a Predictor of Poor Prognosis in Patients With Non-Small-Cell Lung Cancer | Q58454765 | ||
| p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking | Q67841303 | ||
| p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features | Q67841746 | ||
| Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung | Q67857820 | ||
| ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis | Q68119388 | ||
| K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung | Q68532141 | ||
| p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival | Q71045346 | ||
| Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers | Q71093043 | ||
| Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor | Q71961895 | ||
| Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer | Q72301713 | ||
| Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma | Q72365281 | ||
| Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer | Q72940056 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 1125-1130 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer | |
| P478 | volume | 75 |
| Q77748565 | A novel molecular staging protocol for non-small cell lung cancer |
| Q52545817 | Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. |
| Q36895110 | Activation of MEK1/2-ERK1/2 signaling during NNK-induced lung carcinogenesis in female A/J mice |
| Q54673900 | CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer. |
| Q35127312 | Clinical Implication of p53 Mutation in Lung Cancer |
| Q77711290 | Clinical implications of molecular abnormalities in lung cancer |
| Q35008670 | Clinical relevance of molecular markers in lung cancer. |
| Q97592375 | Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer |
| Q52659711 | Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance. |
| Q44069647 | Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma |
| Q37141952 | Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping |
| Q37146779 | Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies |
| Q39785984 | Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer |
| Q40784031 | Differential osteopontin expression in lung cancer |
| Q35211197 | Do all lung adenocarcinomas follow a stepwise progression? |
| Q58596286 | Effects of the expectorant drug ambroxol hydrochloride on chemically induced lung inflammatory and neoplastic lesions in rodents |
| Q36728450 | Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib |
| Q73595241 | Evaluation of p53 alterations in occult lymph node metastases |
| Q77068395 | High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression |
| Q36916714 | Impact of smoking status on the biological behavior of lung cancer |
| Q47791327 | Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma |
| Q26829425 | K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value |
| Q36451726 | KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer |
| Q37963519 | Molecular changes in smoking-related lung cancer |
| Q36772562 | Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer |
| Q34951790 | Molecular staging of lung and esophageal cancer |
| Q38293754 | Mutational analysis of the beta-tubulin gene in lung cancer |
| Q51051494 | Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. |
| Q54719826 | P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma. |
| Q33583984 | Predictive advantage of a cell type classification for pulmonary adenocarcinoma coupled with data for p53, K-ras and EGFR alterations |
| Q35775729 | Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas |
| Q34447423 | Prognostic molecular markers in non-small cell lung cancer |
| Q54771804 | Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. |
| Q40768279 | Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies |
| Q43431016 | Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma. |
| Q48769234 | Pulmonary adenocarcinoma: classification and molecular biology |
| Q50863745 | Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. |
| Q74513452 | Reduced expression of cell-cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer |
| Q54794454 | Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. |
| Q37111920 | Role of DMP1 and its future in lung cancer diagnostics |
| Q33595441 | Role of bronchoscopy in lung cancer research |
| Q38663069 | Selumetinib for the treatment of non-small cell lung cancer |
| Q37378176 | Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung |
| Q89497183 | Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition) |
| Q37581666 | TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis |
| Q43463157 | The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance |
| Q36626149 | The relationship between aberrant methylation and survival in non-small-cell lung cancers |
| Q24650902 | The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis |
| Q40648657 | Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy |
| Q37229930 | Type I insulin-like growth factor receptor induces pulmonary tumorigenesis |
| Q80352865 | [Prognostic indicators in stage I non-small cell lung cancer] |
| Q53306726 | miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. |
| Q36621070 | p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung |
| Q46698755 | p53 and angiogenesis in non-small-cell lung cancer: Reply to the letter from Giatromanolaki and Koukourakis. |
| Q44499462 | p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study |
Search more.